

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

13-18879-01

Docket or Reference number

030-17305

Amendment No. 07

Elkhart General Hospital
600 East Boulevard
Elkhart, IN 46514

In accordance with letter dated April 2, 1985, License Number 13-18879-01 is amended as follows:

Items 6., 7., 8., and 9., are amended to add:

6. Byproduct, source,
and/or special nuclear
material

7. Chemical and/or
physical form

8. Maximum amount that
licensee may possess
at any one time
under this license

F. Any byproduct material
listed in Group VI of
Schedule A, Section
35.100 of 10 CFR 35

F. Any sealed source
listed in Group VI of
Schedule A, Section
35.100 of 10 CFR 35

F. 1 curie
total for all
sources authorized
in Subitem 6.F

9. Authorized Use

F. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

Conditions 12. and 19. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

J. R. Lionberger, M.D.

Groups I, II, III, IV and V
Xenon-133

D. B. Parshall, M.D.

Groups I, II, III, IV and V
Xenon-133

W. S. Tirman, M.D.

Groups I, II, III, IV and V
Xenon-133

J. L. Wind, M.D.

Groups I, II, III, IV and V
Xenon-133

D. S. Chamberlain, M.D.

Groups I, II, III, IV and V
Xenon-133

8506050590 850510
REG3 LIC30
13-18879-01 PDR

COPY

2
mezo

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number	13-18879-01
Docket or Reference number	030-17305
Amendment No. 07	

F. K. Dean, M.D.

Groups I, II and III
Iodine-131 for treatment of
hyperthyroidism and thyroid
carcinoma
Xenon-133

J. L. Grainger, M.D.

Groups I, II, III, IV and V
Xenon-133

F. D. Pairitz, M.D.

Groups I, II and III
Xenon-133

R. W. Ashton, M.D.

Groups I, II and III
Iodine-131 for treatment of
hyperthyroidism and thyroid
carcinoma
Xenon-133

E. Sandou, M.D.

Groups I, II and III
Xenon-133

James C. Field, M.D.

Groups I, II and III
Iodine-131 for treatment of
hyperthyroidism and thyroid
carcinoma
Xenon-133

Robert D. Slabaugh, M.D.

Groups I, II and III
Iodine-131 for treatment of
hyperthyroidism and thyroid
carcinoma
Xenon-133

Thomas A. Bowers, M.D.

Groups I, II and III
Iodine-131 for treatment of
hyperthyroidism and thyroid
carcinoma
Xenon-133

Bernard Sakowicz, M.D.

Groups I, II and III
Phosphorus-32 as soluble phosphate
for the treatment of polycythemia
vera, leukemia, and bone
metastases
Xenon-133

R. P. Tokars, M.D.

Group VI

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

13-18879-01

Docket or Reference number

030-17305

Amendment No. 07

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated February 13, 1980; letters dated November 18, 1980, June 16, 1981, October 22, 1981, April 28, 1982, June 25, 1982, July 8, 1982, January 19, 1983, December 9, 1983 (except Item 1 and Item 3), February 20, 1984 and April 2, 1985; and Model ALARA Program contained in Appendix O of Regulatory Guide 10.8, October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Original Signed

By George M. McCann

Materials Licensing Section, Region III

COPY

Date May 10, 1985